In their review, Arslan et al [1] did not describe the status of Helicobacter pylori (H. pylori ) treatment with furazolidone and the resistance to this antibiotic. We have presented different surveys showing the resistance of H. pylori to furazolidone from Asia and South America. The resistance rates varied but were mostly low (< 5%). There are not enough data on its efficacy and resistance in the United States and Europe. H. pylori mutations occurring in the oorD gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the porD gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Additionally, to complete Arslan et al 's statement regarding levofloxacin resistance, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the gyrA gene for the first time. However, the results on these topics are not sufficient, and more worldwide studies are suggested.
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TO THE EDITOR
We have read with great interest the valuable article by Arslan et al [1] , titled "Importance of antimicrobial susceptibility testing for the management of eradi cation in Helicobacter pylori infection". One of the main subjects of the review was the description of the resistance rates of different antibiotics and the potential mechanisms leading to decreased in Helicobacter pylori (H. pylori) antimicrobial susceptibility. However, the authors should consider clarifying two important issues.
The authors did not allude to the status of H. pylori treatment with furazolidone and the resistance to this antibiotic. We have provided existing surveys reporting the resistance of H. pylori to furazolidone in Table 1 .
The resistance rates have been mostly reported to be lower than 5%; however, these rates can vary geographically. Furazolidone is not used widely in the United States and Europe; therefore, there are not enough data on its efficacy and resistance in these regions.
One of the main reasons for the emergence of resistance is related to the extensive use of furazoli done. In addition, regarding the molecular mechanisms, some genetic mutations have been identified. Muta tions occurring in the 2-oxoglutarate:acceptor oxidoreductase (oorD) gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the pyruvate oxidoreductase (porD) gene, including G353A, A356G, C357T, C347T, C347G and C346A, are possibly related to the resistance [2, 3] . The oor and por genes are involved in the generation of acetyl coenzyme A (acetylCoA) and succinylCoA [4] . Despite these findings, additional molecular methods are proposed to reach a better understanding of the mechanisms that were mentioned.
Arslan et al [1] accurately documented the mech anism of levofloxacin resistance; i.e., point mutations in the gyrA (DNA gyrase) gene were stated to be potentially linked to the resistance. However, to complete their statement, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn87 were recently observed in the gyrA gene for the first time. L45F, A55S, A97V, D91N, R130K and G60S are other possible mutations that need to be assessed in studies with broader sample bases [5] . [6] China (Zhejiang) 2010-2012 21 Agar dilution 0.1 Su et al [7] China (Zhejiang) 2009-2014 9687 Agar dilution < 0.01 Ji et al [8] India (Ghaziabad and New Delhi) NA 68 Agar dilution 22.1 Gehlot et al [9] India (Gujarat) 2008-2011 80 Disk diffusion 13.8 Pandya et al [10] Iran (Rasht) 2012-2014 169 Disk diffusion 61. 9 Maleknejad et al [11] Iran ( [12] Iran (Sari) 2009 197 Disk diffusion 61. 4 Abadi et al [13] Iran (Tehran)  2001-2004  135  Disk diffusion  0 Siavoshi et al [14] Iran (Tehran)  2002-2003  24  Disk diffusion  0 Fallahi et al [15] Iran ( [18] South Korea 1994-1999 220 Agar dilution 1. 4 Kim et al [19] Malaysia (Malacca) 2009 90 Epsilometer test 0 Goh et al [20] Pakistan (Karachi) 2008-2013 93 disk diffusion 4.3 Siddiqui et al [21] South America Brazil (Bragança Paulista) NA 90 Agar dilution 4 Mendonça et al [22] Brazil (Bragança Paulista) NA 138 Agar dilution 13 Godoy et al [23] Brazil (Sao Paulo) NA 39 Agar dilution 0 Eisig et al [24] Brazil (Sao Paulo) 2008-2009 77 Agar dilution and disk diffusion 0 Ogata et al [25] Brazil (Sao Paulo) 2008-2009 77 Agar dilution 0 Ogata et al [26] 
